Sept 17 (Reuters) - Eli Lilly's ( LLY ) international

president Patrik Jonsson said on Wednesday the company had

little clarity on the U.S. Food and Drug Administration's new

fast-track review process, cautioning it was too early to assume

the firm would use it for its experimental weight-loss pill

orforglipron.

"There is very little knowledge about this national priority

voucher today. I would not assume we will submit with a national

priority voucher, because we do not fully understand what it

contains," Jonsson told Reuters in an interview.